RUANYUN EDAI TECHNOLOGY INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 10th, 2025 • Ruanyun Edai Technology Inc. • Services-prepackaged software • New York
GENEMBRYOMICS LIMITED UNDERWRITING AGREEMENT [ ] Ordinary SharesUnderwriting Agreement • March 25th, 2025 • GenEmbryomics LTD • Services-medical laboratories • New York
GenEmbryomics Limited, an Australian public company (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WallachBeth Capital, LLC is acting as Representative (the “Representative”, and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative shall have the same meaning as Underwriter as defined herein), an aggregate of 1,095,000 ordinary shares of the Company (the “Ordinary Shares”) and issue warrants to the Representative to purchase up to a total of [*] Ordinary Shares equal to (6%) of the Ordinary Shares sold in such offering in the form set forth in Exhibit A (the “Representative’s Warrant”). The Company also proposes to grant to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, an option (the “Over-allotment Option”) to
WELLCHANGE HOLDINGS COMPANY LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • August 19th, 2024 • Wellchange Holdings Co LTD • Services-prepackaged software • New York
WELLCHANGE HOLDINGS COMPANY LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • March 27th, 2024 • Wellchange Holdings Co LTD • Services-prepackaged software • New York
ContractUnderwriting Agreement • April 18th, 2023 • VCI Global LTD • Services-facilities support management services • New York
This underwriting agreement (this “Agreement”) constitutes the agreement between VCI Global Limited, a company incorporated in the British Virgin Islands (the “Company”), on the one hand, and Boustead Securities, LLC (the “Representative”), for itself as underwriter and as representative of the several underwriters listed on Schedule I hereto (the “Underwriters”), on the other hand, pursuant to which the Underwriters shall serve as the underwriters for the Company in connection with the proposed offering (the “Offering”) by the Company of its Offered Securities (as defined below).
ContractUnderwriting Agreement • November 29th, 2022 • VCI Global LTD • Services-facilities support management services • New York
This underwriting agreement (this “Agreement”) constitutes the agreement between VCI Global Limited, a company incorporated in the British Virgin Islands (the “Company”), on the one hand, and Boustead Securities, LLC (the “Representative”), for itself as underwriter and as representative of the several underwriters listed on Schedule I hereto (the “Underwriters”), on the other hand, pursuant to which the Underwriters shall serve as the underwriters for the Company in connection with the proposed offering (the “Offering”) by the Company of its Offered Securities (as defined below).
REGENCELL BIOSCIENCE HOLDINGS LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • July 20th, 2021 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • New York
The undersigned, Regencell Bioscience Holdings Limited, a corporation incorporated under the laws of the Cayman Islands (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A) an aggregate of 2,300,000 ordinary shares (the “Firm Shares”) par value $0.00001 per share of the Company (“Ordinary Shares”) and (B) at the election of the Representative, (i) up to an additional 345,000 Ordinary Shares (the “Option Shares”, and together with the Firm Shares, the “Shares”). The offering and sale of the Shares contemplated by this Agreement is referred to herein as the “Offering”.
BON NATURAL LIFE LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • June 24th, 2021 • Bon Natural Life LTD • Medicinal chemicals & botanical products • New York
REGENCELL BIOSCIENCE HOLDINGS LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • June 11th, 2021 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • New York
The undersigned, Regencell Bioscience Holdings Limited, a corporation incorporated under the laws of the Cayman Islands (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A) an aggregate of __________ ordinary shares (the “Firm Shares”) par value $0.00001 per share of the Company (“Ordinary Shares”) and (B) at the election of the Representative, (i) up to an additional _______ Ordinary Shares (the “Option Shares”, and together with the Firm Shares, the “Shares”). The offering and sale of the Shares contemplated by this Agreement is referred to herein as the “Offering”.
BON NATURAL LIFE LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • May 14th, 2021 • Bon Natural Life LTD • Medicinal chemicals & botanical products • New York
QILIAN INTERNATIONAL HOLDING GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • December 23rd, 2020 • Qilian International Holding Group LTD • Pharmaceutical preparations • New York
QILIAN INTERNATIONAL HOLDING GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • December 18th, 2020 • Qilian International Holding Group LTD • Pharmaceutical preparations • New York
QILIAN INTERNATIONAL HOLDING GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • November 27th, 2019 • Qilian International Holding Group LTD • Pharmaceutical preparations • New York